Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
260M
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
2.21M
-
Shares change
-
-424K
-
Total reported value, excl. options
-
$2.99M
-
Value change
-
-$1.78M
-
Number of buys
-
10
-
Number of sells
-
-10
-
Price
-
$1.36
Significant Holders of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) as of Q1 2025
29 filings reported holding SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.21M shares
of 260M outstanding shares and own 0.85% of the company stock.
Largest 10 shareholders include BVF INC/IL (918K shares), Sessa Capital IM, L.P. (458K shares), VANGUARD GROUP INC (278K shares), HB Wealth Management, LLC (263K shares), GEODE CAPITAL MANAGEMENT, LLC (84.7K shares), Pathstone Holdings, LLC (50.7K shares), BlackRock, Inc. (22.3K shares), SILVER OAK SECURITIES, INCORPORATED (20.2K shares), Kovitz Investment Group Partners, LLC (19.2K shares), and First PREMIER Bank (19K shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.